HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says

You may also be interested in...

NanoBio's OTC Route For Cold Sore Med Pays Off With GSK Deal

Privately held biotech company NanoBio's novel cold sore treatment is deviating from the Rx market path most new molecules follow by aiming straight for the OTC market with the help of GlaxoSmithKline

NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal

The privately-held biotech chooses a different commercial path for its proprietary product and gains validation for its nano-emulsion delivery platform, NanoStat.

GSK Plans To Wield Aggressive Bolt-On Acquisition Strategy

GlaxoSmithKline is planning on moving aggressively beyond its core prescription drug business with possible bolt-ons in consumer health among other categories, CEO Andrew Witty told investors at a recent Goldman Sachs conference in New York

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts